Possible increase in serum FABP4 level despite adiposity reduction by canagliflozin, an SGLT2 inhibitor

Masato Furuhashi, Megumi Matsumoto, Shinya Hiramitsu, Akina Omori, Marenao Tanaka, Norihito Moniwa, Hideaki Yoshida, Junnichi Ishii, Tetsuji Miura

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Possible increase in serum FABP4 level despite adiposity reduction by canagliflozin, an SGLT2 inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences

Agriculture & Biology

Chemical Compounds